Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer
Oncotarget. 2024 Mar 19;15:238-247. doi: 10.18632/oncotarget.28567.ABSTRACTA clinical trial was conducted to assess the feasibility of enrolling patients with Stage II or III hormone receptor positive (HR+)/HER2-negative breast cancer to pre-operative dual PD-L1/CTLA-4 checkpoint inhibition administered prior to neoadjuvant chemotherapy (NACT). Eight eligible patients were treated with upfront durvalumab and tremelimumab for two cycles. Patients then received NACT prior to breast surgery. Seven patients had baseline and interval breast ultrasounds after combination immunotherapy and the responses were mixed: 3/7 patients e...
Source: Oncotarget - March 19, 2024 Category: Cancer & Oncology Authors: Haven R Garber Sreyashi Basu Sonali Jindal Zhong He Khoi Chu Akshara Singareeka Raghavendra Clinton Yam Lumarie Santiago Beatriz E Adrada Padmanee Sharma Elizabeth A Mittendorf Jennifer K Litton Source Type: research